3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma, Non-Hodgkin
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Leukemia, Hairy Cell
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Noonan syndrome 3
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Medulloblastoma
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Hepatoblastoma
1
Glioma
1
Genomic Instability
1
Ependymoma
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
tremelimumab
2
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
durvalumab
1
cemiplimab
1
balstilimab
1
Vascular Endothelial Growth Factor A
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Ipilimumab
1
Docetaxel
1
Blood Specimen Collection
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Vemurafenib
×
90 days
×
Clear all
No trials found.